PRVA Stock Forecast 2025-2026
Distance to PRVA Price Targets
PRVA Price Momentum
10 Quality Stocks Worth Considering Now
Researching Privia Health (PRVA) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on PRVA and similar high-potential opportunities.
Latest PRVA Stock Price Targets & Analyst Predictions
Based on our analysis of 25 Wall Street analysts, PRVA has a bullish consensus with a median price target of $30.00 (ranging from $21.00 to $40.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $22.92, the median forecast implies a 30.9% upside. This outlook is supported by 21 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Sean Wieland at Piper Sandler, projecting a 74.5% upside. Conversely, the most conservative target is provided by Andrew Mok at Barclays, suggesting a 8.4% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PRVA Analyst Ratings
PRVA Price Target Range
Latest PRVA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PRVA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 21, 2025 | Needham | Ryan MacDonald | Buy | Reiterates | $30.00 |
| Feb 28, 2025 | Canaccord Genuity | Richard Close | Buy | Maintains | $30.00 |
| Feb 28, 2025 | Citizens Capital Markets | Constantine Davides | Market Outperform | Maintains | $29.00 |
| Feb 28, 2025 | Needham | Ryan MacDonald | Buy | Maintains | $30.00 |
| Feb 28, 2025 | Piper Sandler | Sean Wieland | Overweight | Maintains | $40.00 |
| Feb 14, 2025 | JMP Securities | Constantine Davides | Market Outperform | Maintains | $26.00 |
| Jan 15, 2025 | Needham | Ryan MacDonald | Buy | Reiterates | $25.00 |
| Jan 10, 2025 | Needham | Matthew Sheerin | Buy | Initiates | $25.00 |
| Jan 7, 2025 | Stephens & Co. | Overweight | Reiterates | $0.00 | |
| Jan 2, 2025 | Stephens & Co. | Overweight | Reiterates | $0.00 | |
| Dec 16, 2024 | Macquarie | Outperform | Initiates | $0.00 | |
| Nov 29, 2024 | JP Morgan | Lisa Gill | Overweight | Maintains | $28.00 |
| Nov 8, 2024 | Truist Securities | Jailendra Singh | Buy | Maintains | $27.00 |
| Nov 8, 2024 | Barclays | Andrew Mok | Equal-Weight | Maintains | $21.00 |
| Oct 11, 2024 | Keybanc | Matthew Gillmor | Overweight | Initiates | $23.00 |
| Aug 26, 2024 | Baird | Michael Ha | Outperform | Maintains | $24.00 |
| Aug 14, 2024 | RBC Capital | Sean Dodge | Outperform | Reiterates | $28.00 |
| Jul 9, 2024 | Evercore ISI Group | Elizabeth Anderson | Outperform | Maintains | $20.00 |
| May 30, 2024 | Baird | Michael Ha | Outperform | Initiates | $23.00 |
| May 20, 2024 | Barclays | Andrew Mok | Equal-Weight | Maintains | $19.00 |
Privia Health Group Inc. (PRVA) Competitors
The following stocks are similar to Privia Health based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Privia Health Group Inc. (PRVA) Financial Data
Privia Health Group Inc. has a market capitalization of $2.76B with a P/E ratio of 208.0x. The company generates $1.74B in trailing twelve-month revenue with a 0.8% profit margin.
Revenue growth is +4.6% quarter-over-quarter, while maintaining an operating margin of +1.1% and return on equity of +2.6%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Privia Health Group Inc. (PRVA) Business Model
About Privia Health Group Inc.
Healthcare services company enhancing delivery efficiency.
Privia Health Group generates revenue by partnering with medical groups and health plans to integrate technology and manage care quality. It utilizes a cloud-based platform to facilitate communication among healthcare professionals and patients, allowing for improved patient outcomes and provider workflows, particularly in value-based care models.
The company is positioned within the growing healthcare services sector, reflecting significant industry trends towards digital transformation and the shift from fee-for-service to value-based healthcare.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
1,140
CEO
Mr. Parth Mehrotra
Country
United States
IPO Year
2021
Website
www.priviahealth.comPrivia Health Group Inc. (PRVA) Latest News & Analysis
Privia Health, Corcept and three other low-key but high-earnings growth potential stocks to invest in 2025
24 days agoExperts advise investors to seek opportunities in stocks with strong earnings growth potential, rather than focusing solely on mega-cap stocks like Meta, Amazon, and Netflix amid market volatility.
Shifting focus to stocks with strong earnings growth amid market volatility can uncover undervalued opportunities, potentially enhancing portfolio performance and risk management.
Privia Health Group, Inc. (NASDAQ:PRVA) will hold its Q4 2024 earnings conference call on February 27, 2025, at 8:00 AM ET, featuring key executives and analysts from various firms.
The scheduled earnings call for Privia Health may reveal key financial performance indicators and strategic insights, influencing investor sentiment and stock valuation.
Privia Health Group reported 2024 metrics exceeding guidance, with a 35.3% increase in net cash from operations to $109.3M, a year-end cash balance of $491.1M, and no debt.
Privia Health's strong financial metrics, including significant cash flow growth and no debt, indicate robust operational health and potential for continued investor confidence and stock appreciation.
Privia Health (PRVA) Lags Q4 Earnings Estimates
1 month agoPrivia Health (PRVA) reported Q3 earnings of $0.03 per share, missing estimates of $0.06. This is an increase from $0.02 per share in the same quarter last year.
Privia Health's earnings miss may signal operational challenges and impact investor confidence, potentially leading to stock price volatility and reevaluation of growth prospects.
Privia Health (PRVA) reported its revenue and EPS for Q4 2024, prompting a comparison with Wall Street estimates and year-ago figures for performance assessment.
Comparing Privia Health's revenue and EPS to Wall Street estimates and year-ago figures helps gauge its growth trajectory and market expectations, impacting stock valuation and investor sentiment.
Seeking Clues to Privia Health (PRVA) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
1 month agoPrivia Health (PRVA) is set to report its Q4 2024 performance. Investors are advised to examine key metrics beyond just revenue and earnings estimates for a comprehensive analysis.
Key metrics for Privia Health (PRVA) provide insights into its financial health and growth potential, influencing stock valuation and investment decisions for the upcoming quarter.
Frequently Asked Questions About PRVA Stock
What is Privia Health Group Inc.'s (PRVA) stock forecast for 2025?
Based on our analysis of 25 Wall Street analysts, Privia Health Group Inc. (PRVA) has a median price target of $30.00. The highest price target is $40.00 and the lowest is $21.00.
Is PRVA stock a good investment in 2025?
According to current analyst ratings, PRVA has 21 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $22.92. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PRVA stock?
Wall Street analysts predict PRVA stock could reach $30.00 in the next 12 months. This represents a 30.9% increase from the current price of $22.92. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Privia Health Group Inc.'s business model?
Privia Health Group generates revenue by partnering with medical groups and health plans to integrate technology and manage care quality. It utilizes a cloud-based platform to facilitate communication among healthcare professionals and patients, allowing for improved patient outcomes and provider workflows, particularly in value-based care models.
What is the highest forecasted price for PRVA Privia Health Group Inc.?
The highest price target for PRVA is $40.00 from Sean Wieland at Piper Sandler, which represents a 74.5% increase from the current price of $22.92.
What is the lowest forecasted price for PRVA Privia Health Group Inc.?
The lowest price target for PRVA is $21.00 from Andrew Mok at Barclays, which represents a -8.4% decrease from the current price of $22.92.
What is the overall PRVA consensus from analysts for Privia Health Group Inc.?
The overall analyst consensus for PRVA is bullish. Out of 25 Wall Street analysts, 21 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $30.00.
How accurate are PRVA stock price projections?
Stock price projections, including those for Privia Health Group Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
